GLP-1 receptor agonists and myocardial metabolism in atrial fibrillationOA
GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
Atrial fibrillation(AF)is the most common cardiac arrhythmia.Many medical conditions,including hypertension,diabetes,obesity,sleep apnea,and heart failure(HF),increase the risk for AF.Car-diomyocytes have unique metabolic characteristics to maintain adenosine triphosphate production.Significant changes occur in myocardial metabolism in AF.Glucagon-like peptide-1 receptor agonists(GLP-1 RAs)have been used to control blood glucose fluctuations and weight in the treatment of type 2 diabetes mellitus(T2DM)and obesity.GLP-1 RAs have also been shown to reduce oxidative stress,inflammation,autonomic nervous system modulation,and mitochondrial function.This article reviews the changes in metabolic characteristics in cardiomyocytes in AF.Although the clinical trial outcomes are unsatisfactory,the findings demonstrate that GLP-1 RAs can improve myocardial metabolism in the presence of various risk factors,lowering the incidence of AF.
Jiani Zhong;Hang Chen;Qiming Liu;Shenghua Zhou;Zhenguo Liu;Yichao Xiao
Department of Cardiovascular Medicine,Second Xiangya Hospital,Central South University,Changsha,410011,China||Xiangya School of Medicine,Central South University,Changsha,410008,ChinaDepartment of Cardiovascular Medicine,Second Xiangya Hospital,Central South University,Changsha,410011,ChinaCenter for Precision Medicine and Division of Cardiovascular Medicine,Department of Medicine,School of Medicine,University of Missouri,Columbia,MO,65211,USA
Atrial fibrillationGlucagon-like peptide-1 receptor agonistsMetabolism
《药物分析学报（英文）》 2024 (005)
653-665 / 13
This work was supported by the Clinical Medical Technology Innovation Project of Hunan Science and Technology Agency,China(Project No.:2021SK53519).All figures were created with assis-tance from Biorender.com.
评论